This page shows the latest Calliditas news and features for those working in and with pharma, biotech and healthcare.
Calliditas will acquire 62.7% of company for an initial 20.3m. Calliditas is set to acquire a controlling interest in French biotech Genkyotex, gaining access to its lead primary biliary ... Calliditas will acquire 62.7% of Genkyotex in an initial
for this large patient population,” said Renée Aguiar-Lucander, chief executive of Calliditas. ... Calliditas has one competitor in the field, Omeros, which is developing its OMS721 for IgA nephropathy.
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
and bringing products to market will play a key role as we progress development of Nefecon through phase 3 clinical trials”, said Renée Aguiar-Lucander, CEO of Calliditas Therapeutics. ... He said: “I am excited to take on this role at Calliditas.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...